Arnold Yvonne E, Thorens Julien, Bernard Stéphane, Kalia Yogeshvar N
School of Pharmaceutical Sciences, University of Geneva & University of Lausanne, CMU-1 rue Michel Servet, 1211 Geneva 4, Switzerland.
Debiopharm International SA, Chemin Messidor 5-7, 1006 Lausanne, Switzerland.
Pharmaceutics. 2019 Mar 21;11(3):139. doi: 10.3390/pharmaceutics11030139.
Drug absorption across viable porcine intestines was investigated using an Ussing chamber system. The apparent permeability coefficients, , were compared to the permeability coefficients determined in humans in vivo, . Eleven drugs from the different Biopharmaceutical Classification System (BCS) categories absorbed by passive diffusion with published values were used to test the system. The initial experiments measured for each drug after application in a Krebs⁻Bicarbonate Ringer (KBR) buffer and in biorelevant media FaSSIF V2 and FeSSIF V2, mimicking fasted and fed states. Strong sigmoidal correlations were observed between and . Differences in the segmental of antipyrine, cimetidine and metoprolol confirmed the discrimination between drug uptake in the duodenum, jejunum and ileum (and colon); the results were in good agreement with human data in vivo. The presence of the P-gp inhibitor verapamil significantly increased across the ileum of the P-gp substrates cimetidine and ranitidine ( < 0.05). Clotrimazole, a potent CYP3A4 inhibitor, significantly increased of the CYP3A4 substrates midazolam, verapamil and tamoxifen and significantly decreased the formation of their main metabolites. In conclusion, the results showed that this is a robust technique to predict passive drug permeability under fasted and fed states, to identify regional differences in drug permeability and to demonstrate the activity of P-gp and CYP3A4.
使用Ussing chamber系统研究了药物在猪活体肠中的吸收情况。将表观渗透系数与在人体体内测定的渗透系数进行了比较。选用了11种来自不同生物药剂学分类系统(BCS)类别的药物,这些药物通过被动扩散吸收且已公布了相关数值,用于测试该系统。初始实验在应用于Krebs⁻碳酸氢盐林格氏液(KBR)缓冲液以及模拟禁食和进食状态的生物相关介质FaSSIF V2和FeSSIF V2后,测量了每种药物的。观察到和之间存在强烈的S形相关性。安替比林、西咪替丁和美托洛尔在各段的差异证实了十二指肠、空肠、回肠(和结肠)对药物摄取的区分;结果与人体体内数据高度吻合。P-糖蛋白抑制剂维拉帕米的存在显著增加了P-糖蛋白底物西咪替丁和雷尼替丁在回肠的(<0.05)。克霉唑是一种强效的CYP3A4抑制剂,它显著增加了CYP3A4底物咪达唑仑、维拉帕米和他莫昔芬的,并显著降低了它们主要代谢物的形成。总之,结果表明这是一种可靠的技术,可用于预测禁食和进食状态下的被动药物渗透性,识别药物渗透性的区域差异,并证明P-糖蛋白和CYP3A4的活性。